[4] A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla.

[5] Among individuals with chronic HBV infection, emtricitabine treatment results in significant histologic, virologic, and biochemical improvement.

These symptoms are generally mild to moderate in severity, but they caused 1% of clinical trial patients to give up treatment.

The drug works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA.

[9][10] Triangle Pharmaceuticals was acquired in 2003 by Gilead Sciences, which completed development and now markets the product with the brand name Emtriva.